Literature DB >> 23376569

Overexpression of vascular endothelial growth factor receptor 2 in pterygia may have a predictive value for a higher postoperative recurrence rate.

Koray Gumus1, Sarper Karakucuk1, G Ertugrul Mirza1, Hulya Akgun2, Hatice Arda1, Ayse O Oner1.   

Abstract

BACKGROUND: To investigate the expression levels of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor 1 (VEGFR-1) and VEGFR-2 in pterygium and to clarify the prognostic significance of these expressions in pterygia.
METHODS: A total of 40 surgically excised pterygia and 9 normal conjunctivae were immunohistochemically studied applying the streptavidin-biotin method in paraffin-embedded tissue sections. Monoclonal antibodies were targeted against VEGF, VEGFR-1 and VEGFR-2 proteins. At the sixth postoperative month, the recurrence rate was graded on a scale of 1-4.
RESULTS: The mean percentage of VEGF-positive epithelial cells was comparable in pterygium and normal conjunctivae. However, the pterygium group presented higher expression levels of VEGF in pterygia endothelial cells (p=0.05). In terms of VEGFR-1 expression in epithelial cells, no statistically significant difference was found between two groups (p=0.658). However, normal conjunctivae exhibited higher expression levels of VEGFR-1 in endothelial cells (p=0.002). Epithelial cells in pterygium presented higher combined scores of VEGFR-2 (87.5% and 22.2%, respectively) (p=0.013). While higher expression levels of VEGFR-2 were documented in pterygia endothelial cells, no VEGFR-2 immunoreactivity was observed in the endothelial cells of normal conjunctivae (p<0.001). Expression levels of VEGFR-2 in epithelial cells and endothelial cells were positively correlated with the postoperative recurrence grading system (p<0.001 and τ=0.627, p=0.001 and τ=0.508, respectively).
CONCLUSIONS: The results suggest that VEGF may play a key role through VEGFR-2 in the pathogenesis of pterygium. Moreover, overexpression of VEGFR-2 in pterygia may have a predictive value for a higher postoperative recurrence rate. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Conjunctiva

Mesh:

Substances:

Year:  2013        PMID: 23376569     DOI: 10.1136/bjophthalmol-2012-301944

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  11 in total

1.  Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium: one-year follow-up.

Authors:  Angel Nava-Castañeda; Isabel Ulloa-Orozco; Lilia Garnica-Hayashi; Joaquín Hernandez-Orgaz; Maria Carmen Jimenez-Martinez; Yonathan Garfias
Journal:  J Ocul Pharmacol Ther       Date:  2014-11-04       Impact factor: 2.671

Review 2.  Aberrant expression of genes and proteins in pterygium and their implications in the pathogenesis.

Authors:  Qing-Yang Feng; Zi-Xuan Hu; Xi-Ling Song; Hong-Wei Pan
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

3.  Bibliometric analysis and mapping knowledge domain of pterygium: 2000-2019.

Authors:  Yu-Chi Wang; Fang-Kun Zhao; Qian Liu; Zi-Yan Yu; Jing Wang; Jin-Song Zhang
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.779

4.  Validity of a new comprehensive pterygia grading scale for use in clinical research and clinical trial.

Authors:  Ping Huang; Jianyan Huang; Tudor Tepelus; Jyotsna Maram; Srinivas Sadda; Olivia L Lee
Journal:  Int Ophthalmol       Date:  2017-10-27       Impact factor: 2.031

5.  Management of primary pterygium with intra-lesional injection of 5 flurouracil and bevacizumab (Avastin).

Authors:  Noha Ghoz; John Britton; Andrew R Ross; Imran Mohammed; Emily Hogan; Dalia G Said; Harminder S Dua
Journal:  Eye (Lond)       Date:  2019-06-19       Impact factor: 3.775

6.  Induction of endothelial RAGE expression in pterygium.

Authors:  Samar Al-Swailem; Zhenhua Xu; Lijuan Wu; Matthew J Hartsock; Samuel C Yiu; Elia J Duh
Journal:  Mol Vis       Date:  2014-12-23       Impact factor: 2.367

Review 7.  Recurrent Pterygium: A Review.

Authors:  Leila Ghiasian; Bijan Samavat; Yasaman Hadi; Mona Arbab; Navid Abolfathzadeh
Journal:  J Curr Ophthalmol       Date:  2022-01-06

8.  Conjunctival Lymphangiogenesis Was Associated with the Degree of Aggression in Substantial Recurrent Pterygia.

Authors:  Wei Zhao; Tao Wang; Juan Deng; Lei Zhong; Weilan Huang; Shiqi Ling
Journal:  J Ophthalmol       Date:  2016-01-28       Impact factor: 1.909

9.  MiR-199a-3p/5p participated in TGF-β and EGF induced EMT by targeting DUSP5/MAP3K11 in pterygium.

Authors:  Siying He; Yifang Huang; Shiqi Dong; Chen Qiao; Guohua Yang; Shuai Zhang; Chen Wang; Yuting Xu; Fang Zheng; Ming Yan
Journal:  J Transl Med       Date:  2020-09-01       Impact factor: 5.531

10.  Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials.

Authors:  Yi Sun; Bowen Zhang; Xiuhua Jia; Shiqi Ling; Juan Deng
Journal:  J Ophthalmol       Date:  2018-09-05       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.